A proven and effective choice for OA
treatment trusted by millions
of patients and providers worldwide
Proven efficacy in knees
Significantly superior than placebo
DUROLANE therapy was significantly superior to placebo at week 6 (n=216)

The benefit was greater in patients (n=82) with OA restricted to the study knee

Treatment-related adverse events affected similar numbers of patients in both arms of the study

Significant reductions in pain at 3 months vs. baseline

Highly significant (p<0.001) reductions in pain at 3 months versus baseline as
measured by thevisual analogue scale (VAS) for 103 patients who received
DUROLANE® single injection therapy

80% of these patients reported satisfaction with the treatment
(very good/good/fair)15

Adverse events (5%) were generally transient and did not require medical interventions
31 patients with OA of the hip (according to ACR criteria, WOMAC pain score of at least 7 in one hip and
significant hip pain for the majority of days prior to the study) received a single DUROLANE® injection.
A positive response to treatment was defined as a reduction in WOMAC pain score from baseline of at
least 40%, together with an absolute decrease of at least five points.

For further information and reference material related to this page please down load the Collateral under the Clinical Data tab on the right

Proven efficacy in hips
Reduction in pain and stiffness with improvement in physical function vs. baseline


At three months post-treatment, the overall response rate was 55%

The proportion of patients rating their global status as ‘good or very good’ increased from 0% at baseline to
46% at month three

DUROLANE® was well tolerated with no serious adverse events reported over the three months of
follow-up

Site Design - Pollution Design 2008